This contract expires in 332 days (Sep 19, 2027).

GUIDEHOUSE INC. - CLINICAL DATA MANAGEMENT SUPPORT SERVICES

PIID: 75N98026F00397

Signed Date: Sep 18, 2026Effective Date: Sep 20, 2026End Date: Closes in 332 days

Award $

$3.3M

Vendor

GUIDEHOUSE INC.

NAICS

541611

Signed Date

Sep 18, 2026

Key Details

Dollars Obligated

$3.3M

Base & All Options

$17.4M

Awarding Agency

Department of Health and Human Services

Awarding Sub-Agency

National Institutes of Health

NAICS Code

541611 - ADMINISTRATIVE MANAGEMENT AND GENERAL MANAGEMENT CONSULTING SERVICES

Contract Vehicle

GSA MAS (legacy)

Parent IDIQ (PIID)

GS00F045DA

Product Service Code

R499 - SUPPORT- PROFESSIONAL: OTHER

Extent Competed

FULL AND OPEN COMPETITION

Number of Offers

Place of Performance

BETHESDA, MD

Description

CLINICAL DATA MANAGEMENT SUPPORT SERVICES

Context & Analysis

On Sep 18, 2026, Department of Health and Human Services obligated $3,271,899.2 to GUIDEHOUSE INC. for clinical data management support services. The award is classified under NAICS 541611 — ADMINISTRATIVE MANAGEMENT AND GENERAL MANAGEMENT CONSULTING SERVICES. Competition extent: full and open competition with 3 offers received. Performance is located in BETHESDA, MD. The contract is scheduled through Sep 19, 2027 — approximately 11 months remaining. This award is one of several similar procurements from Department of Health and Human Services under NAICS 541611 — related awards are listed below.

Contractor Information

Contractor: GUIDEHOUSE INC.

UEI: N9NJK877QJK9

Location: MC LEAN, VA

Subcontractors on this Prime(1 disclosed)

First-tier subawards from USASpending’s FSRS reporting. Sub-recipient names are often partially disclosed or redacted; amounts reflect the sub portion only.

Subcontractor	Description	Amount
Not disclosed Sep 21, 2026	THE DIVISION OF INTRAMURAL RESEARCH (DIR) OF THE NATIONAL HEART, LUNG, AND BLOOD INSTITUTE (NHLBI) POSSESS A STRONG CLINICAL RESEARCH PROGRAM WHOSE MISSION IS TO ADVANCE THE DETECTION, DIAGNOSIS, AND TREATMENT OF CARDIOVASCULAR, PULMONARY, AND HEMATOLOGIC-RELATED DISEASES IN HUMANS. THIS MISSION ENTAILS ADMINISTRATION OF CLINICAL TRIALS THAT CAN LATER BE TRANSLATED INTO BROAD CLINICAL PRACTICE, THUS ENABLING ADVANCES IN BASIC SCIENCE TO IMPACT PUBLIC HEALTH. THE DIR TAKES FULL ADVANTAGE OF ITS BASIC AND TRANSLATIONAL RESEARCH ENVIRONMENT IN WHICH PATIENTS CAN BE STUDIED INTENSIVELY TO GAIN VALUABLE PATHOPHYSIOLOGIC INSIGHTS COUPLED WITH BASIC, BENCH RESEARCH TO UNCOVER FUNDAMENTAL MECHANISMS AND FUNCTIONS.	$658,656

Similar Awards

IGF::OT::IGF-PPHF-2013-ELIGIBILITY SUPPORT

SERCO INC

$1.2B

IGF::OT::IGF FOR OTHER FUNCTIONS

HIGHPOINT DIGITAL, INC.

$839.9M

IGF::OT::IGF CCIIO ENROLLMENT RESOLUTION AND RECONCILIATION, FORM 1095-A DATA REPORTING TASK ORDER

COGNOSANTE, LLC

$315.5M

IGF::OT::IGF ELIGIBILITY APPEALS OPERATIONS SUPPORT

MAXIMUS FEDERAL SERVICES, INC.

$286.9M

IGF::OT::IGF THE CERT PROGRAM CALCULATES BI-ANNUAL IMPROPER PAYMENT RATES BASED ON THE RESULTS OF THE REVIEWS CONDUCTED. THESE RATES INCLUDE AN OVERALL NATIONAL MEDICARE FFS IMPROPER PAYMENT RATE AND IMPROPER PAYMENT RATES FOR EACH CLAIM TYPE [PART A INPATIENT HOSPITAL PROSPECTIVE PAYMENT SYSTEM (PPS); PART A EXCLUDING INPATIENT HOSPITAL PPS; PART B; AND DURABLE MEDICAL EQUIPMENT, PROSTHETICS, ORTHOTICS, AND SUPPLIES (DMEPOS)]. THE CERT PROGRAM ENSURES A STATISTICALLY VALID RANDOM SAMPLE; THEREFORE, THE IMPROPER PAYMENT RATE CALCULATED FROM THIS SAMPLE IS CONSIDERED TO BE REFLECTIVE OF ALL OF CLAIMS PROCESSED BY MEDICARE FFS PROGRAM DURING THE REPORT PERIOD. CMS ALSO USES THE CERT PROGRAM TO PERFORM SPECIAL STUDIES AND SUPPLEMENTAL MEASUREMENTS TO DETERMINE THE IMPROPER PAYMENT RATES OF PARTICULAR CLAIM TYPES. CALCULATIONS OF THESE RATES FACILITATE CMS ABILITY TO TAKE APPROPRIATE CORRECTIVE ACTIONS TO REDUCE IMPROPER PAYMENTS.

EMPOWER AI, INC.

$230.2M

View Full Record on USASpending.gov